It’s been nearly five years since Canada enacted the new Certificate of Supplementary Protection (CSP) regime as a result of Canada’s implementation of the Canada-European Union Comprehensive Economic and Trade Agreement (CETA). CSP’s provide for up to two years of additional “patent-like” protection for new pharmaceutical products protected by an eligible patent.
Please join us as Kristin Wall covers a variety of topics related to CSP’s, including:
Kristin Wall is a partner at Norton Rose Fulbright Canada who represents clients in the innovative pharmaceutical industry. She has acted in many of the first litigation proceedings started under the CSP Regulations and has extensive experience in litigation involving the Patented Medicines (Notice of Compliance) Regulations, Food and Drug Regulations and Patented Medicines Regulations. In addition, she advises on issues concerning Health Canada regulation and pricing and reimbursement. In 2021, Kristin was named as one of the top 250 women in intellectual property globally by Managing Intellectual Property and was also named the LMG Life Sciences Canadian Patent Litigator of the Year.
